Zacks Investment Research
30 Apr 2026, 23:26 UTC · 29w ago
Pacira (PCRX) Q1 Earnings Miss Estimates
Impact · against what's priced in
Pacira's Q1 results are marginally disappointing, featuring a slight earnings miss and a negligible revenue beat. The year-over-year decline in EPS suggests a trend of shrinking profitability that may weigh on the stock.
- PCRX−0.20
No priced-in read yet
- In context
Pacira missed EPS estimates with $0.60 versus $0.61 expected, and earnings decreased from $0.62 a year ago, offsetting a marginal revenue beat of $177.38 million.
Read from the article alone





